Karlton Wong, MD
Hematology & Oncology · Burbank, CANPI 1376962381
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,035 of the $2,891 with a category attached, or 70.4%. 20 manufacturers reported payments, led by GSK at 30.8% of the total. Reporting peaked in 2021 at $1,101 and has fallen 75.6% since, to $269 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 39 payments — averaging $74.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$891
- Exelixis Inc.$864
- Seagen Inc.$230
- Daiichi Sankyo Inc.$142
- Deciphera Pharmaceuticals Inc.$141
- Genentech USA, Inc.$121
- plus $502 from 14 others
Across 72 payments — averaging $5797.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$320K
- AbbVie$27K
- Janssen Research & Development, LLC$24K
- Seagen Inc.$16K
- Pfizer$15K
- Eli Lilly$13K
- plus $3K from 2 others
What the payments were for
- Consulting fees$82529%
- Food & beverage$2,03570%
- Education$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 3 | $891 |
| Exelixis Inc. | 1 | $864 |
| Seagen Inc. | 6 | $230 |
| Daiichi Sankyo Inc. | 5 | $142 |
| Deciphera Pharmaceuticals Inc. | 2 | $141 |
| Genentech USA, Inc. | 1 | $121 |
| Pfizer | 5 | $114 |
| Amgen | 2 | $58 |
| Agios Pharmaceuticals, Inc. | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Karyopharm Therapeutics Inc. | 1 | $34 |
| Merck | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Bristol Myers Squibb | 1 | $26 |
| Incyte Corporation | 1 | $24 |
| EMD Serono, Inc. | 1 | $23 |
| Pulmonx Corporation | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| AbbVie | 1 | $21 |
| Novartis | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,891 in reported general payments places this provider in the 45th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 45 | $746,120 |
| VerzenioAbemaciclib | 23 | $443,435 |
| Lenalidomide | 27 | $388,425 |
| IbrancePalbociclib | 24 | $328,180 |
| ZejulaNiraparib Tosylate | 12 | $202,971 |
| CalquenceAcalabrutinib Maleate | 12 | $184,229 |
| BrukinsaZanubrutinib | 11 | $169,483 |
| Imatinib Mesylate | 13 | $149,872 |
| EliquisApixaban | 121 | $103,861 |
| JakafiRuxolitinib Phosphate | 11 | $88,495 |
| XareltoRivaroxaban | 24 | $18,258 |
| Diclofenac Sodium | 15 | $4,216 |
| Exemestane | 30 | $2,025 |
| Anastrozole | 92 | $1,778 |
| Enoxaparin Sodium | 15 | $1,569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $26 | $746,12045 claims |
| PfizerIbrance, Eliquis | $114 | $432,041145 claims |
| GSKZejula | $891 | $202,97112 claims |
| Incyte CorporationJakafi | $24 | $88,49511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Burbank
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.